Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery: A cohort study from Taiwan

Chien-Mu Lin, Po Ting Yeh, Pat Doyle, Yu Tse Tsan, Pau Chung Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The risk of cataracts after 131I therapy for cancer is unknown. The objective of this study was to evaluate the association between 131I therapy for thyroid cancer and risk of receiving cataract surgery in Taiwan. Methods: This was a nationwide populationbased cohort study of patients with thyroid cancer diagnosed during the period 1998-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I activity in each patient was calculated. Hazard ratios were calculated using a time-dependent survival analysis to estimate the effect of 131I therapy on the risk of receiving cataract surgery. Results: A total of 8,221 patients were eligible for the final analysis (mean age, 43.2 y; mean follow-up, 5.9 y); 69% received 131I with a median cumulative activity of 3.7 GBq. Two hundred patients received cataract surgery. The adjusted hazard ratios were 0.77 (95% confidence interval, 0.54-1.09), 0.92 (95% CI, 0.64-1.31), and 1.06 (95% CI, 0.58- 1.94) for cumulative 131I activities of 0.1-3.6, 3.7-7.3, and 7.4 GBq or more, respectively, compared with a cumulative activity of 0. No trend was noted (P > 0.85). No interaction between 131I activity and age or between 131I activity and sex was noted (all P > 0.05). Conclusion: 131I treatment for thyroid cancer did not increase the risk of receiving cataract surgery up to 10 y after treatment. However, further research with direct lens examination and a longer follow-up period is needed to assess subtle and late adverse effects beyond 10 y.

Original languageEnglish
Pages (from-to)836-841
Number of pages6
JournalJournal of Nuclear Medicine
Volume57
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Taiwan
Thyroid Neoplasms
Cataract
Cohort Studies
Therapeutics
National Health Programs
Survival Analysis
Research
Lenses
Confidence Intervals
Neoplasms

Keywords

  • Cataract
  • Iodine radioisotopes
  • Thyroid neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Radiology Nuclear Medicine and imaging

Cite this

Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery : A cohort study from Taiwan. / Lin, Chien-Mu; Yeh, Po Ting; Doyle, Pat; Tsan, Yu Tse; Chen, Pau Chung.

In: Journal of Nuclear Medicine, Vol. 57, No. 6, 01.06.2016, p. 836-841.

Research output: Contribution to journalArticle

Lin, Chien-Mu ; Yeh, Po Ting ; Doyle, Pat ; Tsan, Yu Tse ; Chen, Pau Chung. / Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery : A cohort study from Taiwan. In: Journal of Nuclear Medicine. 2016 ; Vol. 57, No. 6. pp. 836-841.
@article{5ca3ded07f4b41ccb85a4792d90ec268,
title = "Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery: A cohort study from Taiwan",
abstract = "The risk of cataracts after 131I therapy for cancer is unknown. The objective of this study was to evaluate the association between 131I therapy for thyroid cancer and risk of receiving cataract surgery in Taiwan. Methods: This was a nationwide populationbased cohort study of patients with thyroid cancer diagnosed during the period 1998-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I activity in each patient was calculated. Hazard ratios were calculated using a time-dependent survival analysis to estimate the effect of 131I therapy on the risk of receiving cataract surgery. Results: A total of 8,221 patients were eligible for the final analysis (mean age, 43.2 y; mean follow-up, 5.9 y); 69{\%} received 131I with a median cumulative activity of 3.7 GBq. Two hundred patients received cataract surgery. The adjusted hazard ratios were 0.77 (95{\%} confidence interval, 0.54-1.09), 0.92 (95{\%} CI, 0.64-1.31), and 1.06 (95{\%} CI, 0.58- 1.94) for cumulative 131I activities of 0.1-3.6, 3.7-7.3, and 7.4 GBq or more, respectively, compared with a cumulative activity of 0. No trend was noted (P > 0.85). No interaction between 131I activity and age or between 131I activity and sex was noted (all P > 0.05). Conclusion: 131I treatment for thyroid cancer did not increase the risk of receiving cataract surgery up to 10 y after treatment. However, further research with direct lens examination and a longer follow-up period is needed to assess subtle and late adverse effects beyond 10 y.",
keywords = "Cataract, Iodine radioisotopes, Thyroid neoplasms",
author = "Chien-Mu Lin and Yeh, {Po Ting} and Pat Doyle and Tsan, {Yu Tse} and Chen, {Pau Chung}",
year = "2016",
month = "6",
day = "1",
doi = "10.2967/jnumed.115.167197",
language = "English",
volume = "57",
pages = "836--841",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery

T2 - A cohort study from Taiwan

AU - Lin, Chien-Mu

AU - Yeh, Po Ting

AU - Doyle, Pat

AU - Tsan, Yu Tse

AU - Chen, Pau Chung

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The risk of cataracts after 131I therapy for cancer is unknown. The objective of this study was to evaluate the association between 131I therapy for thyroid cancer and risk of receiving cataract surgery in Taiwan. Methods: This was a nationwide populationbased cohort study of patients with thyroid cancer diagnosed during the period 1998-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I activity in each patient was calculated. Hazard ratios were calculated using a time-dependent survival analysis to estimate the effect of 131I therapy on the risk of receiving cataract surgery. Results: A total of 8,221 patients were eligible for the final analysis (mean age, 43.2 y; mean follow-up, 5.9 y); 69% received 131I with a median cumulative activity of 3.7 GBq. Two hundred patients received cataract surgery. The adjusted hazard ratios were 0.77 (95% confidence interval, 0.54-1.09), 0.92 (95% CI, 0.64-1.31), and 1.06 (95% CI, 0.58- 1.94) for cumulative 131I activities of 0.1-3.6, 3.7-7.3, and 7.4 GBq or more, respectively, compared with a cumulative activity of 0. No trend was noted (P > 0.85). No interaction between 131I activity and age or between 131I activity and sex was noted (all P > 0.05). Conclusion: 131I treatment for thyroid cancer did not increase the risk of receiving cataract surgery up to 10 y after treatment. However, further research with direct lens examination and a longer follow-up period is needed to assess subtle and late adverse effects beyond 10 y.

AB - The risk of cataracts after 131I therapy for cancer is unknown. The objective of this study was to evaluate the association between 131I therapy for thyroid cancer and risk of receiving cataract surgery in Taiwan. Methods: This was a nationwide populationbased cohort study of patients with thyroid cancer diagnosed during the period 1998-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131I activity in each patient was calculated. Hazard ratios were calculated using a time-dependent survival analysis to estimate the effect of 131I therapy on the risk of receiving cataract surgery. Results: A total of 8,221 patients were eligible for the final analysis (mean age, 43.2 y; mean follow-up, 5.9 y); 69% received 131I with a median cumulative activity of 3.7 GBq. Two hundred patients received cataract surgery. The adjusted hazard ratios were 0.77 (95% confidence interval, 0.54-1.09), 0.92 (95% CI, 0.64-1.31), and 1.06 (95% CI, 0.58- 1.94) for cumulative 131I activities of 0.1-3.6, 3.7-7.3, and 7.4 GBq or more, respectively, compared with a cumulative activity of 0. No trend was noted (P > 0.85). No interaction between 131I activity and age or between 131I activity and sex was noted (all P > 0.05). Conclusion: 131I treatment for thyroid cancer did not increase the risk of receiving cataract surgery up to 10 y after treatment. However, further research with direct lens examination and a longer follow-up period is needed to assess subtle and late adverse effects beyond 10 y.

KW - Cataract

KW - Iodine radioisotopes

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84973663756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973663756&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.167197

DO - 10.2967/jnumed.115.167197

M3 - Article

C2 - 26837336

AN - SCOPUS:84973663756

VL - 57

SP - 836

EP - 841

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -